An appraisal of drug development timelines in the Era of precision oncology

The effects of incorporating a biomarker-based (personalized or precision) selection strategy on drug development timelines for new oncology drugs merit investigation. Here we accessed documents from the Food and Drug Administration (FDA) database for anticancer agents approved between 09/1998 and 0...

Descripción completa

Detalles Bibliográficos
Autores principales: Jardim, Denis Leonardo, Schwaederle, Maria, Hong, David S., Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288167/
https://www.ncbi.nlm.nih.gov/pubmed/27419632
http://dx.doi.org/10.18632/oncotarget.10588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288167/
https://www.ncbi.nlm.nih.gov/pubmed/27419632
http://dx.doi.org/10.18632/oncotarget.10588

Ejemplares similares